Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012

Cancer Epidemiology

Volumn 36, Issue 1, 2012, Pages

  Pulte, Dianne ^a   Gondos, Adam ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Geriatric population; Non Hodgkin lymphoma; Period analysis; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; EMPIRICAL RESEARCH; EXPECTATION; FEMALE; FOLLICULAR LYMPHOMA; GROUPS BY AGE; HUMAN; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SEER PROGRAM; SURVIVAL RATE; SURVIVORS; UNITED STATES;

EID: 84855855313     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.08.006     Document Type: Article

References (24)

1. Pulte D., Gondos A., Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990 to the early 21st century. Arch Intern Med 2008, 168(5):469-476.
2. Pulte D., Gondos A., Brenner H. Long term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma 2009, 50(2):179-186.
3. Gondos A., Bray F., Hakulinien T., Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009, 20(3):564-573. EUNICE Survival Working Group.
4. Brenner H., Gefeller O. An alternative approach to the monitoring of cancer patient survival. Cancer 1996, 78:2004-2010.
5. Brenner H., Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002, 20(3):826-832.
6. Surveillance, Epidemiology, and End Results (SEER) Program () Limited-Use Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2011, based on the November 2010 submission. http://www.seer.cancer.gov/.
7. Brenner H., Hakulinen T. Up-to-date estimates of cancer patient survival even with common latency in cancer registration. Cancer Epidemiol Biomarkers Prevent 2006, 15:1727-1732.
8. Gondos A., Holleczek B., Janssen-Heijnen M., Brewster D.H., Bray F., Rosso S., et al. Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation. Int J Cancer 2009, 125(11):2666-2672.
9. Brenner H., Gondos A., Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94(2):270-275.
10. Pulte D., Gondos A., Brenner H. Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol 2010, 21(2):335-341.
11. Brenner H., Gondos A., Pulte D. Survival expectations of patients diagnosed with Hodgkin lymphoma in 2006-2010. The Oncologist 2009, 14:806-813.
12. Morton L.M., Turner J.J., Cernan J.R., Linet M.S., Treseler P.A., Clarke C.A., et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007, 110(2):695-708.
13. Ederer F., Axtell L.M., Cutler S.J. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-121.
14. Henson D.E., Ries L.A. The relative survival rate. Cancer 1995, 76:1687-1688.
15. Ederer F., Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10 1959, National Cancer Institute, Bethesda, MD.
16. Arias E. United States life tables, 2000. Natl Vit Stat Rep 2002, 51:1-39.
17. Brenner H., Gefeller O., Hakulinen T. Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Eur J Cancer 2004, 40:326-335.
18. Han X., Kilfoy B., Zhen T., Holford T.R., Zhu C., Zhu Y., Zhang Y. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008, 19(8):848-851.
19. Hiddemann W. Non-Hodgkin's lymphomas-current status of therapy and future perspectives. Eur J Cancer 1995, 31A(13-14):2141-2145.
20. Pfreundschuh M., Truemper L., Osterborg A., Petterngell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabTherap International Trial (MInT) group. Lancet Oncol 2006, 7(5):379-391.
21. Czuczman M.S., Weaver R., Alkuzweny B., Berlfein J., Grillo-Lopez A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22(23):4711-4716.
22. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Onocol 2002, 29(2 Suppl. 6):18-22.
23. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcomes of diffuse large B-cell lymphoma in British Columbia. J Clin Orthod 2005, 23(22):5027-5033.
24. Joensson B., Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol 2007, 18(Suppl. 3):iii1-iii77.